Laventair Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long\-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Laventair Ellipta is used for maintenance (regular) treatment. Laventair Ellipta contains the active substances umeclidinium bromide and vilanterol.
Therapeutic Indication
Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Therapeutic Area (MeSH)
ATC Code
R03AL03
ATC Item
N/A
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| umeclidinium bromide | N/A | umeclidinium bromide |
| vilanterol | N/A | vilanterol |
EMA Name
Laventair Ellipta (previously Laventair)
Medicine Name
Laventair Ellipta (previously Laventair)
Aliases
N/ANo risk management plan link.
